Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT03219268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03219268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2017
Completion date
February 8, 2023
Enrollment
277 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cervical cancer, cholangiocarcinoma, hematologic neoplasms, her2-positive advanced solid tumors, non small cell lung cancer, ovarian cancer, small-cell lung cancer, squamous cell carcinoma of head and neck, tnbc - triple-negative breast cancer